BRCA1 Genotype

A BRCA1 result answers a question a routine blood panel never touches: whether you inherited a specific genetic change that makes breast and ovarian cancer far more likely than average. It is one of the few tests where a single answer can reshape decades of screening and prevention decisions.

This is a once-in-a-lifetime test. The genotype you were born with does not change, but knowing it early gives you years to act before any cancer would appear.

Breast Cancer Risk

BRCA1 (breast cancer gene 1) is a tumor-suppressor gene, which means its normal job is to help cells fix damaged DNA and keep them from turning cancerous. When you inherit a harmful change in this gene, that repair system works poorly, and cancer risk climbs sharply.

In a large prospective study of women carrying a harmful BRCA1 variant, about 72 out of 100 developed breast cancer by age 80. Earlier prospective work put the figure near 60% by age 70, and a meta-analysis across ten studies estimated 57% by age 70. The exact number shifts with the study population, but every estimate points to a risk several times higher than average.

Risk is not fixed across all carriers. When researchers combined common gene variants that nudge risk up or down, estimated lifetime breast cancer risk ranged from 28% to 50% among the lowest-risk 5% of BRCA1 carriers up to 81% to 100% among the highest-risk 5%. Risk also rises with the number of close relatives affected.

Ovarian Cancer Risk

Ovarian cancer is the second major threat tied to BRCA1, and it carries extra weight because there is no reliable routine screening test for it. Knowing your genotype in advance is often the only way to get ahead of it.

In the same prospective study, about 44 out of 100 BRCA1 carriers developed ovarian cancer by age 80. Other estimates range from roughly 40% to 59% by age 70, and in Asian carriers the figure fell between about 31% and 42% depending on ancestry and birth year. As with breast cancer, the precise risk depends on the specific variant and family background.

Cancers Beyond the Breast and Ovaries

BRCA1 is not only a breast-and-ovary story. In a Japanese registry of 100,914 people, harmful BRCA1 variants were linked to biliary tract cancer, with about 17 times the odds, and gastric cancer, with about 5 times the odds.

Large studies also connect BRCA1 to male breast, pancreatic, and stomach cancer, and a meta-analysis found a raised colorectal cancer risk in BRCA1 carriers. Prostate cancer risk in male carriers is real but less certain than it is for the related BRCA2 gene, and depends heavily on study design.

Why Two Carriers Can Have Very Different Risk

A harmful BRCA1 result is not a single risk label. Variants that cut the protein short, called truncating variants, tend to carry higher breast cancer risk and worse outcomes in young patients. Some single-letter changes, called missense variants, carry noticeably lower risk, especially after age 50.

Specific variants can behave in surprising ways. A reduced-penetrance variant known as p.Arg1699Gln carried only about a 20% breast and 6% ovarian cancer risk by age 70, far below the classic high-risk figures. An Italian founder variant, p.His1673del, raised ovarian cancer risk but not breast cancer risk in the families studied.

These seeming contradictions resolve once you stop treating BRCA1 as one on-off switch. The exact variant, where it sits in the gene, your ancestry, and your background of common gene variants all shape the actual number. That is why the specific variant listed on your report matters far more than the word BRCA1 alone.

A Result You Only Need Once

Your BRCA1 genotype was set at conception and never changes, so this is a once-in-a-lifetime test. There is no trend to track and no reason to repeat it, with one exception: a result that came from a screening chip should be confirmed by full gene sequencing before you rely on it.

The value comes from what you do with the answer over the following decades, not from retesting the gene. A positive result is a reason to begin earlier and more frequent surveillance and to weigh risk-reducing options. In carriers, risk-reducing removal of the breasts has cut breast cancer incidence by 85% to 100%, and removal of the ovaries and tubes has cut ovarian cancer risk by about 80%, with some specialist-center studies reporting reductions above 90%.

Structured surveillance also catches disease early. In an Asian cohort of carriers, screening found breast cancers at the earliest, most treatable stage 89.1% of the time, with no breast cancer deaths among carriers who developed cancer during follow-up. That is the payoff of knowing your genotype years ahead of any symptom.

Why the Testing Method Matters

Not all BRCA1 tests are equal. Screening chips, the kind used by many direct-to-consumer ancestry services, caught only about 35 out of 100 true carriers, and when they flagged a variant as present they were wrong roughly 96% of the time. Full gene sequencing is close to 100% accurate for the changes it reads.

Even sequencing has a blind spot. Large structural rearrangements, where whole chunks of the gene are duplicated or deleted, can slip past sequencing alone and need an added technique called MLPA (a method that measures whether the right number of gene copies is present). A high-quality BRCA1 test pairs the two.

When a Result Can Mislead You

A BRCA1 result is only as informative as the question it was built to answer. A few situations can lead you to the wrong conclusion:

• What the test covers: a negative result only rules out the specific variants the assay was designed to detect. It does not rule out harmful changes in related inherited cancer genes such as PALB2, CHEK2, and ATM; in high-risk families that tested negative for BRCA1 and BRCA2, roughly 5% to 14% still carried a pathogenic variant in another gene depending on the cohort.
• Your ancestry: which variants matter varies by background, and variants of uncertain meaning are more common in people of non-European or mixed ancestry, which can make a clean answer harder to reach.
• Germline versus tumor: a BRCA1 change found in a tumor sample is not automatically inherited. It must be confirmed in normal, non-tumor DNA to know whether it runs in your family.
• Variants of uncertain significance (VUS): sometimes a change is reported whose effect is genuinely unknown. This is not a positive result and should not drive surgery or screening changes on its own.

What to Do With an Unexpected Result

A positive pathogenic result is a starting point, not an endpoint. If it came from a screening chip, confirm it by sequencing before acting. Then involve a genetic counselor or a clinician trained in hereditary cancer to map out surveillance and prevention tailored to your specific variant and family history.

Two combinations deserve special attention. A pathogenic result plus a strong family history points toward the most intensive surveillance. A negative result alongside a strong family history is a reason to order a broader multigene panel rather than to relax, since the family risk may sit in a gene that BRCA1 testing does not cover.

A positive result also matters for the people around you. Each of your siblings and children has about a 50% chance of carrying the same variant, so encouraging biological relatives to consider testing, known as cascade testing, is a standard next step.